Provided by Tiger Trade Technology Pte. Ltd.

Immunocore Holdings plc

36.88
+0.60001.65%
Post-market: 36.880.00000.00%19:30 EDT
Volume:329.45K
Turnover:12.10M
Market Cap:1.90B
PE:-103.42
High:36.98
Open:36.70
Low:35.68
Close:36.28
52wk High:40.71
52wk Low:27.56
Shares:51.50M
Float Shares:45.83M
Volume Ratio:0.70
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3566
EPS(LYR):-0.7054
ROE:-4.47%
ROA:-0.16%
PB:4.52
PE(LYR):-52.28

Loading ...

Immunocore says Phase 1 brenetafusp data show 87% 6-month survival in advanced melanoma patients

Reuters
·
May 31

Immunocore Shareholders Back All Proposals at 2026 AGM

TIPRANKS
·
May 28

Immunocore shareholders back all AGM resolutions on poll vote

Reuters
·
May 28

Immunocore publishes corporate presentation on bispecific soluble TCR immunomodulating medicines

Reuters
·
May 13

Immunocore (IMCR) Is Up 9.7% After Strong Q1 Results And KIMMTRAK Survival Data Release

Simply Wall St.
·
May 11

Immunocore (IMCR) Returns To Quarterly Profit And Tests Bearish Profitability Narratives

Simply Wall St.
·
May 08

Immunocore Holdings PLC reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

UK's Immunocore Q1 profit beats estimates

Reuters
·
May 06

Immunocore Q1 net income rises to $13 million; KIMMTRAK net sales climb 13.6% to $106.7 million

Reuters
·
May 06

Immunocore Hldgs Q1 EPS $0.25 Beats $(0.25) Estimate, Sales $106.677M Miss $107.731M Estimate

Benzinga Earnings
·
May 06

Immunocore Reports First Quarter Financial Results and Provides a Business Update

THOMSON REUTERS
·
May 06

Immunocore Q1 Operating Income USD 7.28 Million VS. Ibes Estimate USD -16.4 Million

THOMSON REUTERS
·
May 06

Immunocore Holdings PLC expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
May 01

How Investors Are Reacting To Immunocore (IMCR) Five-Year KIMMTRAK Survival Data In Uveal Melanoma

Simply Wall St.
·
Apr 29

H.C. Wainwright Remains a Buy on Immunocore Holdings (IMCR)

TIPRANKS
·
Apr 23

Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 21

Immunocore (IMCR): KIMMTRAK’s Durable Survival Benefit in Metastatic Uveal Melanoma Underpins Sustainable Growth and $100 Buy Rating

TIPRANKS
·
Apr 20

Immunocore announces five-year overall survival data for Kimmtrak

TIPRANKS
·
Apr 20

Immunocore says Kimmtrak lifts 5-year survival to 16% in metastatic uveal melanoma trial

Reuters
·
Apr 20

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR)

TIPRANKS
·
Apr 15